Enzymes as a special class of therapeutic target: clinical drugs and modes of action

Current Opinion in Structural Biology

Volumn 17, Issue 6, 2007, Pages 674-679

  Robertson, James G ^a  

^a Softzymics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; ALISKIREN; AMINO ACID TRANSFER RNA LIGASE; AN2690; DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; IMMUCILLIN H; L PRO L BOROPRO; MITOGEN ACTIVATED PROTEIN KINASE; PURINE NUCLEOSIDE PHOSPHORYLASE; RENIN; S ADENOSYLHOMOCYSTEINE; SAXAGLIPTIN; SITAGLIPTIN; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VILDAGLIPTIN;

DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

DRUG APPROVAL; ENZYME INHIBITORS; ENZYMES; HUMANS; SUBSTRATE SPECIFICITY;

EID: 36549063511     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sbi.2007.08.008     Document Type: Review

References (38)

1. Robertson J.G. Mechanistic basis of enzyme-targeted drugs. Biochemistry 44 (2005) 5561-5571
2. Robinson D.R., Wu Y.M., and Lin S.F. The protein tyrosine kinase family of the human genome. Oncogene 19 (2000) 5548-5557
3. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., Harris P.L., Driscoll D.R., Fidias P., Lynch T.J., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102 (2005) 7665-7670
4. Janus A., Robak T., and Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 10 (2005) 479-498
5. Wood J.M., Maibaum J., Rahuel J., Grutter M.G., Cohen N.C., Rasetti V., Ruger H., Goschke R., Stutz S., Fuhrer W., et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 308 (2003) 698-705
6. Gradman A.H., Schmieder R.E., Lins R.L., Nussberger J., Chiang Y., and Bedigian M.P. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111 (2005) 1012-1018
7. Mentlein R., Gallwitz B., and Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214 (1993) 829-835
8. Deacon C.F., Johnsen A.H., and Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80 (1995) 952-957
9. Deacon C.F., Hughes T.E., and Holst J.J. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47 (1998) 764-769
10. Flentke G.R., Munoz E., Huber B.T., Plaut A.G., Kettner C.A., and Bachovchin W.W. Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci U S A 88 (1991) 1556-1559
11. Gutheil W.G., and Bachovchin W.W. Separation of l-Pro-DL-boroPro into its component diastereomers and kinetic analysis of their inhibition of dipeptidyl peptidase IV. A new method for the analysis of slow, tight-binding inhibition. Biochemistry 32 (1993) 8723-8731
12. Oefner C., D'Arcy A., Mac Sweeney A., Pierau S., Gardiner R., and Dale G.E. High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano-(S)-pyrrol idine. Acta Crystallogr D Biol Crystallogr 59 (2003) 1206-1212
13. Peters J.U. 11 Years of cyanopyrrolidines as DPP-IV inhibitors. Curr Top Med Chem 7 (2007) 579-595
14. Thornberry N.A., and Weber A.E. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem 7 (2007) 557-568
15. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., Mangold B.L., Russell M.E., and Hughes T.E. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46 (2003) 2774-2789
16. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G., Wang A., Simpkins L.M., Taunk P., Huang Q., et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48 (2005) 5025-5037
17. Lienhard G.E. Enzymatic catalysis and transition-state theory. Science 180 (1973) 149-154
18. Wolfenden R. Transition state analog inhibitors and enzyme catalysis. Annu Rev Biophys Bioeng 5 (1976) 271-306
19. Radzicka A., and Wolfenden R. A proficient enzyme. Science 267 (1995) 90-93
20. Radzicka A., and Wolfenden R. Transition state and multisubstrate analog inhibitors. Methods Enzymol 249 (1995) 284-312
21. Schramm V.L. Enzymatic transition states and transition state analog design. Annu Rev Biochem 67 (1998) 693-720
22. Schramm V.L. Enzymatic transition-state analysis and transition-state analogs. Methods Enzymol 308 (1999) 301-355
23. Schramm V.L. Enzymatic transition states and transition state analogues. Curr Opin Struct Biol 15 (2005) 604-613
24. Schramm V.L. Enzymatic transition states: thermodynamics, dynamics and analogue design. Arch Biochem Biophys 433 (2005) 13-26
25. Miles R.W., Tyler P.C., Furneaux R.H., Bagdassarian C.K., and Schramm V.L. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry 37 (1998) 8615-8621
26. Biocryst: http://www.biocryst.com/. 2007.
27. Lewandowicz A., and Schramm V.L. Transition state analysis for human and Plasmodium falciparum purine nucleoside phosphorylases. Biochemistry 43 (2004) 1458-1468
28. Lewandowicz A., Tyler P.C., Evans G.B., Furneaux R.H., and Schramm V.L. Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J Biol Chem 278 (2003) 31465-31468
29. Evans G.B., Furneaux R.H., Schramm V.L., Singh V., and Tyler P.C. Targeting the polyamine pathway with transition-state analogue inhibitors of 5′-methylthioadenosine phosphorylase. J Med Chem 47 (2004) 3275-3281
30. Evans G.B., Furneaux R.H., Lenz D.H., Painter G.F., Schramm V.L., Singh V., and Tyler P.C. Second generation transition state analogue inhibitors of human 5′-methylthioadenosine phosphorylase. J Med Chem 48 (2005) 4679-4689
31. Basu I., Cordovano G., Das I., Belbin T.J., Guha C., and Schramm V.L. A transition state analogue of 5′-methylthioadenosine phosphorylase induces apoptosis in head and neck cancers. J Biol Chem (2007)
32. Singh V., Lee J.E., Nunez S., Howell P.L., and Schramm V.L. Transition state structure of 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Escherichia coli and its similarity to transition state analogues. Biochemistry 44 (2005) 11647-11659
33. Singh V., Evans G.B., Lenz D.H., Mason J.M., Clinch K., Mee S., Painter G.F., Tyler P.C., Furneaux R.H., Lee J.E., et al. Femtomolar transition state analogue inhibitors of 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Escherichia coli. J Biol Chem 280 (2005) 18265-18273
34. Bull H.G., Calvo M.G., Andersson S., Baginsky W.F., Chan H.K., Ellsworth D.E., Miller R.R., Stearns R.A., Bakshi R.K., Rasmusson G.H., et al. Mechanism-based inhibition of human steroid 5a-reductase by finasteride: enzyme-catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor. Am Chem Soc 118 (1996) 2359-2365
35. Rozwarski D.A., Grant G.A., Barton D.H., Jacobs Jr. W.R., and Sacchettini J.C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279 (1998) 98-102
36. Hughes J., and Mellows G. Interaction of pseudomonic acid A with Escherichia coli B isoleucyl-tRNA synthetase. Biochem J 191 (1980) 209-219
37. Pope A.J., Lapointe J., Mensah L., Benson N., Brown M.J., and Moore K.J. Characterization of isoleucyl-tRNA synthetase from Staphylococcus aureus. I: Kinetic mechanism of the substrate activation reaction studied by transient and steady-state techniques. J Biol Chem 273 (1998) 31680-31690
38. Rock F.L., Mao W., Yaremchuk A., Tukalo M., Crepin T., Zhou H., Zhang Y.K., Hernandez V., Akama T., Baker S.J., et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 316 (2007) 1759-1761